{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;} {\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;} {\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;} {\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;} {\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;} {\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;} {\s6\tqc\lang1033\sbasedon0\snext6 footer;} {\*\cs16 \additive\super\sbasedon10 footnote reference;} {\*\cs18 \additive\sbasedon10 page number;}} {\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}} {\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;\red153\green153\blue153;} {\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb88\cf1\f51\fs36\b\qc UNITED STATES\par\pard\plain\cf1\f51\fs36\b\qc SECURITIES AND EXCHANGE COMMISSION\par\pard\plain\cf1\f51\fs24\b\qc Washington, D.C. 20549\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb264\cf1\f51\fs36\b\qc FORM\~8-K\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb264\cf1\f51\fs24\b\qc CURRENT REPORT\par\pard\plain\cf1\f51\fs24\b\qc PURSUANT TO SECTION\~13 OR 15(D)\par\pard\plain\cf1\f51\fs24\b\qc OF THE SECURITIES EXCHANGE ACT OF 1934\par\pard\plain\sb264\cf1\f51\fs24\b\qc Date of Report (Date of earliest event reported): August\~27, 2018\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb264\cf1\f51\fs48\b\qc AKEBIA THERAPEUTICS, INC.\par\pard\plain\cf1\f51\fs20\b\qc (Exact name of registrant as specified in its charter)\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs24\ql \~ \par\pard\plain {\trowd\clvertalc\cellx3671\clvertalb\cellx3779\clvertalc\cellx7235\clvertalb\cellx7342\clvertalc\cellx10800\trrh66 \pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{ {\trowd\clvertalc\cellx3671\clvertalb\cellx3779\clvertalc\cellx7235\clvertalb\cellx7342\clvertalc\cellx10800\trrh66\row}}} {\trowd\cellx3671\clvertalb\cellx3779\cellx7235\clvertalb\cellx7342\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\b\qc Delaware\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 001-36352\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 20-8756903\cell{ {\trowd\cellx3671\clvertalb\cellx3779\cellx7235\clvertalb\cellx7342\cellx10800\trrh248\row}}} {\trowd\cellx3671\clvertalb\cellx3779\cellx7235\clvertalb\cellx7342\cellx10800\trrh418 \pard\plain\intbl\cf1\f51\fs16\b\qc (State or other jurisdiction\par\pard\plain\intbl\sa22\cf1\f51\fs16\b\qc of incorporation)\cell\pard\plain\intbl\cf1\f51\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (Commission\par\pard\plain\intbl\sa22\cf1\f51\fs16\b\qc File Number)\cell\pard\plain\intbl\cf1\f51\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (IRS Employer\par\pard\plain\intbl\sa22\cf1\f51\fs16\b\qc Identification No.)\cell{ {\trowd\cellx3671\clvertalb\cellx3779\cellx7235\clvertalb\cellx7342\cellx10800\trrh418\row}}}\pard\plain\cf1\f51\fs24\ql \~ \par\pard\plain {\trowd\clvertalc\cellx5436\clvertalb\cellx5580\clvertalc\cellx10800\trrh66 \pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{ {\trowd\clvertalc\cellx5436\clvertalb\cellx5580\clvertalc\cellx10800\trrh66\row}}} {\trowd\cellx5436\clvertalb\cellx5580\clvertalb\cellx10800\trrh518 \pard\plain\intbl\cf1\f51\fs20\b\qc 245 First Street\par\pard\plain\intbl\sa22\cf1\f51\fs20\b\qc Cambridge, Massachusetts\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 02142\cell{ {\trowd\cellx5436\clvertalb\cellx5580\clvertalb\cellx10800\trrh518\row}}} {\trowd\cellx5436\clvertalb\cellx5580\cellx10800\trrh198 \pard\plain\intbl\cf1\f51\fs16\b\qc (Address of principal executive offices)\cell\pard\plain\intbl\cf1\f51\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (Zip Code)\cell{ {\trowd\cellx5436\clvertalb\cellx5580\cellx10800\trrh198\row}}}\pard\plain\sb264\cf1\f51\fs20\b\qc Registrant\u8217?s telephone number, including area code:\~(617) 871-2098\par\pard\plain\sb264\cf1\f51\fs20\b\qc n/a\par\pard\plain\cf1\f51\fs16\b\qc (Former name or former address, if changed since last report)\par\pard\plain\cf1\f51\fs24\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~\par\pard\plain\sb264\cf1\f51\fs20\ql Check the appropriate box below if the Form\~8-K filing is intended to simultaneously satisfy the filing obligation of the\plain\cf1\f51\fs20\ql registrant under any of the following provisions:\par\pard\plain\cf1\f51\fs12\ql \~ \par\pard\plain {\trowd\cellx664\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \u9744?\cell\pard\plain\intbl\cf1\f51\fs20\ql Written communications pursuant to Rule\~425 under the Securities Act (17 CFR 230.425)\cell{ {\trowd\cellx664\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs12\ql \~ \par\pard\plain {\trowd\cellx664\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \u9744?\cell\pard\plain\intbl\cf1\f51\fs20\ql Soliciting material pursuant to Rule\~14a-12 under the Exchange Act (17 CFR 240.14a-12)\cell{ {\trowd\cellx664\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs12\ql \~ \par\pard\plain {\trowd\cellx664\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \u9744?\cell\pard\plain\intbl\cf1\f51\fs20\ql Pre-commencement communications pursuant to Rule\~14d-2(b)\~under the Exchange Act (17 CFR 240.14d-2(b))\cell{ {\trowd\cellx664\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs12\ql \~ \par\pard\plain {\trowd\cellx664\cellx10800\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql \u9744?\cell\pard\plain\intbl\cf1\f51\fs20\ql Pre-commencement communications pursuant to Rule\~13e-4(c)\~under the Exchange Act (17 CFR 240.13e-4(c))\cell{ {\trowd\cellx664\cellx10800\trrh248\row}}}\pard\plain\sb264\fi462\cf1\f51\fs20\ql Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act\plain\cf1\f51\fs20\ql of 1933 (\u167?230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u167?240.12b-2 of this\plain\cf1\f51\fs20\ql chapter).\par\pard\plain\sb264\fi462\cf1\f51\fs20\ql Emerging growth company\~\~\u9746?\par\pard\plain\sb264\fi462\cf1\f51\fs20\ql If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition\plain\cf1\f51\fs20\ql period for complying with any new or revised financial accounting standards provided pursuant to Section\~13(a) of the Exchange\plain\cf1\f51\fs20\ql Act.\~\~\u9746?\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa44\cf1\f51\fs20\ql \~ \page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par{\*\bkmkstart part_1_2_1}{\*\bkmkend part_1_2_1}{\*\bkmkstart item_1_41_1}{\*\bkmkend item_1_41_1}\par\pard\plain\cf1\f51\fs20\b\ql Item\~5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;\plain\cf1\f51\fs20\b\ql Compensatory Arrangements of Certain Officers.\par\pard\plain\sb132\fi462\cf1\f51\fs20\ql On August\~27, 2018, the Board of Directors (the \u8220?Board\u8221?) of Akebia Therapeutics, Inc., a Delaware\plain\cf1\f51\fs20\ql corporation (the \u8220?Company\u8221?), increased the Board\u8217?s size from eight to nine directors and elected Cynthia\plain\cf1\f51\fs20\ql Smith as a Class\~II director to fill the resulting vacancy, effective August\~28, 2018. As a Class\~II director, Ms.\~Smith\u8217?s\plain\cf1\f51\fs20\ql initial term is scheduled to expire at the Company\u8217?s 2019 annual meeting of stockholders. The Board has not yet\plain\cf1\f51\fs20\ql determined on which Board committees Ms.\~Smith will serve.\par\pard\plain\sb264\fi462\cf1\f51\fs20\ql There are no arrangements or understandings between Ms.\~Smith and any other persons, pursuant to which she was selected\plain\cf1\f51\fs20\ql as a director.\par\pard\plain\sb264\fi462\cf1\f51\fs20\ql Ms.\~Smith is entitled to receive compensation pursuant to the Company\u8217?s Amended and Restated Non-Employee\plain\cf1\f51\fs20\ql Director Compensation Program (the \u8220?Program\u8221?) applicable to all of the Company\u8217?s\~non-employee\~directors.\plain\cf1\f51\fs20\ql In accordance with the Program, Ms.\~Smith is eligible for an annual cash retainer of $40,000 for serving on the Board, and on\plain\cf1\f51\fs20\ql August\~28, 2018, was granted an option to purchase 25,000 shares of common stock of the Company. Ms.\~Smith will also have\plain\cf1\f51\fs20\ql the same right to indemnification by the Company as granted to the Company\u8217?s other non-employee directors.\par\pard\plain\cf1\f51\fs16\ql \~\par\pard\plain\cf1\f51\fs20\qc 2 \page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par{\*\bkmkstart part_1_2_2}{\*\bkmkend part_1_2_2}\par\pard\plain\cf1\f51\fs20\b\qc SIGNATURE\par\pard\plain\sb264\fi462\cf1\f51\fs20\ql Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed\plain\cf1\f51\fs20\ql on its behalf by the undersigned hereunto duly authorized.\par\pard\plain\cf1\f51\fs24\ql \~ \par\pard\plain {\trowd\clvertalc\cellx728\clvertalb\cellx1456\clvertalc\cellx4320\trrh66 \pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{ {\trowd\clvertalc\cellx728\clvertalb\cellx1456\clvertalc\cellx4320\trrh66\row}}} {\trowd\cellx4320\trrh248 \pard\plain\intbl\cf1\f51\fs20\b\ql AKEBIA THERAPEUTICS,\~INC.\cell{ {\trowd\cellx4320\trrh248\row}}} {\trowd\clvertalc\cellx4320\trrh66 \pard\plain\intbl\f0\fs16\ql \~\cell{ {\trowd\clvertalc\cellx4320\trrh66\row}}} {\trowd\clbrdrb\brdrs\brdrcf1\cellx4320\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql /s/ John P. Butler\cell{ {\trowd\clbrdrb\brdrs\brdrcf1\cellx4320\trrh248\row}}} {\trowd\clvertalb\cellx728\clvertalb\cellx1456\clvertalb\cellx4320\trrh248 \pard\plain\intbl\cf1\f51\fs20\ql Name:\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql John P. Butler\cell{ {\trowd\clvertalb\cellx728\clvertalb\cellx1456\clvertalb\cellx4320\trrh248\row}}} {\trowd\clvertalb\cellx728\clvertalb\cellx1456\clvertalb\cellx4320\trrh495 \pard\plain\intbl\cf1\f51\fs20\ql Title:\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql President and Chief Executive\plain\intbl\cf1\f51\fs20\ql Officer\cell{ {\trowd\clvertalb\cellx728\clvertalb\cellx1456\clvertalb\cellx4320\trrh495\row}}}\pard\plain\sb264\cf1\f51\fs20\ql Date: August 28, 2018\par\pard\plain\cf1\f51\fs16\ql \~\par\pard\plain\cf1\f51\fs20\qc 3}